All In Biotech

NDA 050722 · Roche Palo

Cellcept

Mycophenolate Mofetil · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

May 3, 1995

Approved uses

6

Original approval plus efficacy supplements

Registered trials

1,151

212 Phase 3, 106 recruiting

FAERS reports

138,802

126,629 serious, 24,926 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions (5.1) , Use in Special Populations (8.1 , 8.3) ] . Increased risk of development of lymphoma and other malignancies, particularly of the skin [see Warnings and Precautions (5.2) ] . Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes [see Warnings and Precautions (5.3) ] . WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS See full prescribing information for...

What it is approved for

From the label in effect Aug 5, 2026.

CELLCEPT [mycophenolate mofetil (MMF)] is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ], heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ] , in combination with other immunosuppressants. CELLCEPT is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. ( 1 )

Mechanism: Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CELLCEPT · MYCOPHENOLATE MOFETIL 250MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mycophenolate Mofetil" as an intervention, any sponsor and status, largest first.

All 1,151 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use20,344
  • drug ineffective11,621
  • product use in unapproved indication7,426
  • diarrhoea7,211
  • pyrexia5,839
  • pneumonia5,519
  • cytomegalovirus infection5,007
  • fatigue4,809
  • nausea4,737
  • condition aggravated4,653
  • dyspnoea4,390
  • vomiting4,236

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004773
2005865
20061,201
20071,359
20081,722
20092,396
20102,298
20112,496
20122,714
20132,861
20143,111
20153,703
20164,508
20177,331
20188,478
201910,703
202011,592
202110,644
202210,127
202311,130
202414,284
202514,302
202610,195

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cellcept (Mycophenolate Mofetil)

2024 spending

$4.1M

Beneficiaries

361

1,688 claims

Per beneficiary

$11,320

$14.12 per unit

View as table
YearSpending
2020$8,373,785
2021$6,817,241
2022$5,963,581
2023$5,317,386
2024$4,086,555

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,008 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.